Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

CytokineticsCEORobertBlumspokelastweekatatalkduringSTAT’sBreakthroughSummitWestinSanFrancisco.SarahG SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We




focus

author：comprehensive    Page View：8
Patient treated with Impella in the heart. -- health tech coverage from STAT
Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

advertisement

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Some medical students still think black patients feel less pain
Next article： Tori Bowie and the unacceptable rates of Black maternal death